Uridine

solute carrier family 29 member 1 (Augustine blood group) ; Homo sapiens







23 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 35264969 Structure-Activity Relationship Studies of 4-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-6-imino-N-(naphthalen-2-yl)-1,3,5-triazin-2-amine (FPMINT) Analogues as Inhibitors of Human Equilibrative Nucleoside Transporters. 2022 1
2 33262250 Predicting Drug Interactions with Human Equilibrative Nucleoside Transporters 1 and 2 Using Functional Knockout Cell Lines and Bayesian Modeling. 2021 Feb 1
3 33426680 Fluorouracil uptake in triple-negative breast cancer cells: Negligible contribution of equilibrative nucleoside transporters 1 and 2. 2021 Mar 1
4 32393653 Nucleoside Reverse Transcriptase Inhibitor Interaction with Human Equilibrative Nucleoside Transporters 1 and 2. 2020 Jul 2
5 31177538 Dietary supplement with nucleotides in the form of uridine monophosphate or uridine stimulate intestinal development and promote nucleotide transport in weaned piglets. 2019 Oct 1
6 30254099 Role of cysteine 416 in N-ethylmaleimide sensitivity of human equilibrative nucleoside transporter 1 (hENT1). 2018 Oct 31 2
7 30469356 mRNA Expression and Activity of Nucleoside Transporters in Human Hepatoma HepaRG Cells. 2018 Nov 21 1
8 28365185 Curcumin and its cyclohexanone analogue inhibited human Equilibrative nucleoside transporter 1 (ENT1) in pancreatic cancer cells. 2017 May 15 1
9 27432881 Selective Inhibition of Human Equilibrative and Concentrative Nucleoside Transporters by BCR-ABL Kinase Inhibitors: IDENTIFICATION OF KEY hENT1 AMINO ACID RESIDUES FOR INTERACTION WITH BCR-ABL KINASE INHIBITORS. 2016 Sep 2 2
10 24788480 Synthesis of purine and 7-deazapurine nucleoside analogues of 6-N-(4-Nitrobenzyl)adenosine; inhibition of nucleoside transport and proliferation of cancer cells. 2014 Sep 1
11 21539390 Design, synthesis, and evaluation of 2-diethanolamino-4,8-diheptamethyleneimino-2-(N-aminoethyl-N-ethanolamino)-6-(N,N-diethanolamino)pyrimido[5,4-d]pyrimidine-fluorescein conjugate (8MDP-fluor), as a novel equilibrative nucleoside transporter probe. 2011 Jun 15 1
12 20814156 Human erythrocyte nucleoside transporter ENT1 functions at ice-cold temperatures. 2010 3
13 19699178 Disrupted plasma membrane localization and loss of function reveal regions of human equilibrative nucleoside transporter 1 involved in structural integrity and activity. 2009 Oct 1
14 17121826 Molecular determinants of substrate selectivity of a novel organic cation transporter (PMAT) in the SLC29 family. 2007 Feb 2 3
15 17706182 Synthesis, transportability and hypoxiaselective binding of 1-beta-D-(5-Deoxy-5-fluororibofuranosyl)-2-nitroimidazole (beta-5-FAZR), a configurational isomer of the clinical hypoxia marker, FAZA. 2007 1
16 15644498 Residue 33 of human equilibrative nucleoside transporter 2 is a functionally important component of both the dipyridamole and nucleoside binding sites. 2005 Apr 1
17 15649894 Identification and mutational analysis of amino acid residues involved in dipyridamole interactions with human and Caenorhabditis elegans equilibrative nucleoside transporters. 2005 Mar 25 1
18 15043160 Uridine recognition motifs of human equilibrative nucleoside transporters 1 and 2 produced in Saccharomyces cerevisiae. 2004 7
19 11814344 A single glycine mutation in the equilibrative nucleoside transporter gene, hENT1, alters nucleoside transport activity and sensitivity to nitrobenzylthioinosine. 2002 Feb 5 3
20 12062437 PKC regulation of the human equilibrative nucleoside transporter, hENT1. 2002 Apr 24 1
21 12416024 Correlation of nucleoside and nucleobase transporter gene expression with antimetabolite drug cytotoxicity. 2002 Jul-Aug 2
22 12440703 Comparison of the interaction of uridine, cytidine, and other pyrimidine nucleoside analogues with recombinant human equilibrative nucleoside transporter 2 (hENT2) produced in Saccharomyces cerevisiae. 2002 3
23 9705281 Chimeric constructs between human and rat equilibrative nucleoside transporters (hENT1 and rENT1) reveal hENT1 structural domains interacting with coronary vasoactive drugs. 1998 Aug 21 1